Aprea Therapeutics, Inc Earning Date (APRE)

USA |NASDAQ |USD

APRE Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Aug 10, 2022 Jun 2022 - - $-0.48
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Aug 10, 2022 Jun 2022 - - $0.00

Aprea Therapeutics, Inc's next earnings date is Wednesday, Aug 10, 2022 for the fiscal quarter ending Jun 2022.

APRE Earnings Date & History Chart

APRE Earnings & Revenue Forecast

APRE Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 5 $-1.57 $-2.02 $-1.25

APRE Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2022 2 / 0 $-1.63 $-1.63 $-1.63

APRE Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 5 $0.00 $0.00 $0.00

APRE Earnings Date & Revenue History

APRE Earnings History

|
Show More
Show More

APRE Revenue History

|
Show More
Show More

Aprea Therapeutics, Inc Next Earnings Date & Report

APRE Next Earnings Date & Report Preview: Jun 2022 (FQ)

APRE's next earnings date is Wednesday, Aug 10, 2022 for the fiscal quarter ending Jun 30, 2022.

Aprea Therapeutics, Inc Previous Earnings Dates & Reports

APRE Previous Earnings Date & Report Recap: Mar 2022 (FQ)

Aprea Therapeutics, Inc's previous earnings date was May 5, 2022 for its fiscal quarter ended Mar 31, 2022.

APRE Previous Earnings Date & Report Recap: Dec 2021 (FY)

Aprea Therapeutics, Inc's previous annual earnings date was Mar 15, 2022 for its fiscal year ended Dec 31, 2021.

APRE's earnings per share (EPS) was $-1.75, missing the consensus analysts forecast of $-1.74 by 0.57% , and higher than the previous year's EPS (Dec 2020) by -31.10%.

Revenues were $0.00.

The company reported a net income of $-37.13B.

Aprea Therapeutics, Inc reported a free cash flow of $-37.69M for its fiscal year, compared to $-41.83M a year ago.